Krystal Biotech (KRYS) EBIAT (2021 - 2025)
Historic EBIAT for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $79.4 million.
- Krystal Biotech's EBIAT rose 19199.78% to $79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 27980.22%. This contributed to the annual value of $89.2 million for FY2024, which is 71557.81% up from last year.
- Per Krystal Biotech's latest filing, its EBIAT stood at $79.4 million for Q3 2025, which was up 19199.78% from $38.3 million recorded in Q2 2025.
- Over the past 5 years, Krystal Biotech's EBIAT peaked at $80.7 million during Q3 2023, and registered a low of -$50.0 million during Q1 2022.
- Moreover, its 5-year median value for EBIAT was -$15.6 million (2021), whereas its average is $2.3 million.
- Per our database at Business Quant, Krystal Biotech's EBIAT crashed by 21599.42% in 2022 and then skyrocketed by 373401.29% in 2025.
- Quarter analysis of 5 years shows Krystal Biotech's EBIAT stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then skyrocketed by 127.12% to $8.7 million in 2023, then soared by 423.23% to $45.5 million in 2024, then surged by 74.51% to $79.4 million in 2025.
- Its EBIAT stands at $79.4 million for Q3 2025, versus $38.3 million for Q2 2025 and $35.7 million for Q1 2025.